Embedding Evidence and Evaluation in Economic Recovery Legislation
Summary
The COVID-19 pandemic has had devastating impacts on communities across the country. Tens of millions of people lost jobs and millions of school children have fallen behind. To help people recover from the effects of the pandemic, the next administration should invest in proven solutions by working with Congress to embed evaluation and evidence-building into economic stimulus legislation, strengthening the foundation for an equitable and efficient recovery.
The new administration and Congress should ensure that any forthcoming economic stimulus legislation include provisions requiring commitments to build new evidence and utilize existing evidence. Specifically, the administration should establish a task force coordinated by the National Economic Council to:
- Work with agencies and Congress to set aside a portion of recovery resources (up to 1%) for evaluation and evidence-building, based in part on agency learning agendas created in response to the Evidence Act.
- Create a National Economic Mobility Innovation Fund at the U.S. Department of the Treasury.
- Empower the Office of Evaluation Services (OES) within the General Services Administration (GSA) to help agencies develop evaluation and evidence-building capacity.
- Create Excellence in What Works in Economic Mobility Awards.
These strategies, which we are collectively calling a “Stimulus Evaluation Act,” should be integrated into current and future economic recovery efforts.
AI is transforming how children learn and live, and policymakers, industry, and educators owe it to the next generation to set in place a responsible policy that embraces this new technology while at the same time ensuring all children’s well-being, privacy, and safety is respected.
A peer support option should be integrated into the 988 Suicide and Crisis Lifeline so that 988 service users can choose to connect with specialists based on a shared lived experience.
Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.